{
  "source": "PA-Med-Nec-Enbrel.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2197-11\nProgram Prior Authorization/Medical Necessity\nMedication Enbrel® (etanercept)\nP&T Approval Date 5/2020, 11/2020, 6/2021, 9/2021, 12/2021, 3/2022, 6/2022, 11/2022,\n7/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nEnbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of\nrheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years\nof age or older, psoriatic arthritis (PsA) in patients 2 years of age or older, ankylosing\nspondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of one non-biologic disease modifying\nanti-rheumatic drug (DMARD) [e.g., methotrexate, leflunomide,\nsulfasalazine, hydroxychloroquine] at maximally indicated doses, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial)b\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of rheumatoid arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi\n(golimumab), Olumiant (baricitinib), Rinvoq (upadacitinib),\nXeljanz/Xeljanz XR (tofacitinib)]\n-OR-\n(c) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\ni. Patient is currently on Enbrel therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Amgen sponsored",
    "rds (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Amgen sponsored\nEnbrel Support program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Enbrel*\n-AND-\n(3) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Amgen sponsored Enbrel Support program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Polyarticular Juvenile Idiopathic Arthritis (PJIA)\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n2\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib",
    "t receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(3) Prescribed by or in consultation with a rheumatologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) One of the following:\n(a) History of failure to a 3 month trial of methotrexate at maximally indicated\ndose, unless contraindicated or clinically significant adverse effects are\nexperienced (document date and duration of trial)b\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of psoriatic arthritis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Simponi\n(golimumab), Stelara (ustekinumab), Tremfya (guselkumab),\nXeljanz/Xeljanz XR (tofacitinib), Otezla (apremilast), Skyrizi\n(risankizumab), Rinvoq (upadacitinib)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Enbrel therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the ",
    "of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Amgen sponsored\nEnbrel Support program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Enbrel*\n-AND-\n(3) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Amgen sponsored Enbrel Support program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n4\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Plaque Psoriasis\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n(1) Diagnosis of chroni",
    "Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Plaque Psoriasis\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n(1) Diagnosis of chronic moderate to severe plaque psoriasis\n-AND-\n(2) One of the following:\n(a) All of the following:\ni. Greater than or equal to 3% body surface area involvement,\npalmoplantar, facial, genital involvement, or severe scalp psoriasis\n-AND-\nii. History of failure to one of the following topical therapies, unless\ncontraindicated or clinically significant adverse effects are experienced\n(document drug, date, and duration of trial):\na. Corticosteroids (e.g., betamethasone, clobetasol, desonide)\nb. Vitamin D analogs (e.g., calcitriol, calcipotriene)\nc. Tazarotene\nd. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\ne. Anthralin\nf. Coal tar\n-AND-\niii. History of failure to of a 3 month trial of methotrexate at maximally\nindicated dose, unless contraindicated or clinically significant adverse\neffects are experienced (document date and duration of trial)b\n-OR-\n© 2024 UnitedHealthcare Services, Inc.\n5\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of plaque psoriasis as documented by claims\nhistory or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., Cimzia (certolizumab), adalimumab, Otezla\n(apremilast), Skyrizi (risankizumab), Stelara (ustekinumab), Tremfya\n(guselkumab)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Enbrel therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Amgen sponsored\nEnbrel Support program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Enbrel*\n-AND-\n(3) Patient is not re",
    "ponsored\nEnbrel Support program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Enbrel*\n-AND-\n(3) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\n-AND-\n(4) Prescribed by or in consultation with a dermatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Amgen sponsored Enbrel Support program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n© 2024 UnitedHealthcare Services, Inc.\n6\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nE. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Enbrel will be approved based on all of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, ",
    "f the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) One of the following:\n(a) History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally\nindicated doses, each used for at least 4 weeks, unless contraindicated or\nclinically significant adverse effects are experienced (document drug, date,\nand duration of trials)\n-OR-\n(b) Patient has been previously treated with a targeted immunomodulator FDA-\napproved for the treatment of ankylosing spondylitis as documented by\nclaims history or submission of medical records (Document drug, date, and\nduration of therapy) [e.g., adalimumab, Simponi (golimumab)]\n-OR-\n(c) Both of the following:\ni. Patient is currently on Enbrel therapy as documented by claims history or\nsubmission of medical records (Document date and duration of therapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from the Amgen sponsored\nEnbrel Support program (e.g., sample card which can be redeemed at a\npharmacy for a free supply of medication) as a means to establish as a\ncurrent user of Enbrel*\n© 2024 UnitedHealthcare Services, Inc.\n7\n-AND-\n(3) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a rheumatologist\n* Patients requesting initial authorization who were established on therapy via the\nreceipt of a manufacturer supplied sample at no cost in the prescriber’s office or any\nform of assistance from the Amgen sponsored Enbrel Support program shall be\nrequired to meet initial authorization criteria as if patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical",
    "f patient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\nb For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation.; October 2023.\n© 2024 UnitedHealthcare Services, Inc.\n8\n2. Ward MM, Deodhar, A, Gensler, LS, et al. 2019 Update of the American College of\nRheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment\nNetwork Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic\nAxial Spondyloarthritis. Arthritis & Rheumatology. 2019; 71(10): 1599-1613.\n3. Yu, DT, van Tubergen A. Treatment of axial spondyloarthritis (ankylosing spondylitis and\nnonradiographic axial spondyloarthritis) in adults. Sieper, J (Ed). UpToDate. Waltham, MA:\nUpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)\n4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Gu",
    "Ed). UpToDate. Waltham, MA:\nUpToDate Inc. http://www.uptodate.com (Accessed on October 10, 2019.)\n4. Singh, JA, Guyatt, G, et al. 2018 American College of Rheumatology/National Psoriasis\nFoundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019;\n71(1): 5-32.\n5. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of\npsoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.\n6. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis\nand psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for treatment with an\nemphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.\n7. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis\nwith topical therapies. J Am Acad Dermatol 2009;60(4):643-59.\n8. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and\nphotochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.\n9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and\npsoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with\ntraditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.\n10. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris – update\n2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm Venereol\n2015;29:2277-94.\n11. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic ar",
    ", Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care for\nthe management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment\nof psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J\nAm Acad Dermatol. 2011 Jul;65(1):137-74.\n12. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for the\nmanagement of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis\n2016;75:499-510.\n13. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management\nand treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.\nProgram Prior Authorization/Medical Necessity - Enbrel (etanercept)\nChange Control\n5/2020 New program\n6/2020 Administrative change. Updated formatting numbers for psoriatic\narthritis section with no change to clinical intent.\n11/2020 Revised step therapy medications for psoriatic arthritis and psoriasis\ndue to expanded indications. Removed continuation of therapy\nallowance.\n6/2021 Removed prescriber requirement from reauthorization criteria. Added\ncoverage criteria for patients previously treated with a biologic\nDMARD.\n© 2024 UnitedHealthcare Services, Inc.\n9\n9/2021 Revised step requirements for rheumatoid arthritis, psoriatic arthritis,\nplaque psoriasis, and ankylosing spondylitis. Updated background and\nreferences.\n12/2021 Updated the following with no change to clinical intent: updated\nconventional DMARD bypass language for rheumatoid arthritis,\npsoriatic arthritis and psoriasis, removed “biologic” from required\npreferred product criteria language, updated age requirement language\nand updated CT/KY footnote.\n3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.\n6/2022 Added Rinvoq and Xeljanz as step therapy options for ankylosing\nspondylitis and psoriatic arthritis.\n11/2022 Removed step requirement through preferred products and added\ncontinutation of therapy for RA, PsA, P",
    "oq and Xeljanz as step therapy options for ankylosing\nspondylitis and psoriatic arthritis.\n11/2022 Removed step requirement through preferred products and added\ncontinutation of therapy for RA, PsA, PsO, and AS.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria. Updated\nbackground, state mandate footnote, and reference.\n© 2024 UnitedHealthcare Services, Inc.\n10"
  ]
}